Anaplasma marginalefield challenge: Protection by an inactivated immunogen that shares partial sequence ofmsp1[alpha]variable region with the challenge strain

• Published in: Vaccine Vol. 25; no. 3; p. 519
• Main Authors: Vega, Laura E Orozco, Rodríguez, Sergio D, Alarcón, Germinal J Cantó, Flores, Rafael López, Ocampo, Rafael Jiménez, Ortiz, Miguel Ángel García, de la Torre, Jesús Francisco Preciado, Ramírez, Edmundo E Rojas
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 05-01-2007
• Subjects: Animals; Cattle; Experiments; Genetic diversity; Immunization; Proteins; Mexico
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2006.07.049

Twenty four Hereford heifers free of anaplasmosis were allotted into three groups of eight animals each and inoculated three times with adjuvant in Puck saline as control or 50μg and 100μg of total protein ofAnaplasma marginaleinitial bodies from three Mexican strains which share the same variable region ofmsp1αandmsp4. Inoculation with the adjuvant or the immunogen at either of the two protein doses did not induce any undesirable changes attributable to inoculation in vaccinates or controls. On day 78 post vaccination animals were released in a ranch where bovine Anaplasmosis is endemic. TheA. marginalestrain prevalent in this ranch shares some of themsp1αtandem repeats with and the strains used in the vaccine. After release, all animals became infested withBoophilus microplusticks and flies. During the challenge period, between days 279 and 300, loss of PCV due to clinical anaplasmosis in control animals was statistically higher from vaccinated animals. Likewise, controls mean peak rickettsemia was also significantly higher (p<=0.01) than vaccinates' rickettsemias. The antibody responses of all vaccinates after the third vaccination reached OD values above 2.0 on day 49 and were different from controls (p<0.01). IgG2responses from both groups of vaccinates were different from controls (p<0.01). Vaccinates which required treatment, also showed the lowest IgG2and substantial IgG1responses. After contact with the rickettsia, controls developed clinical disease and 7 out of 8 required treatment, while vaccinates in general showed no substantial changes in hematocrit or rickettsemia and only one animal in each group required treatment. Our present results show that vaccination with either 50μg or 100μg of protein from purified IB derived from three strains induced protection to resist the challenge with the a field strain that shares some of the tandem repeats of MSP1a